| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
CZC-25146 is a potent, selective, and metabolically stable LRRK2 inhibitor (Leucine-rich repeat kinase-2) with IC50 of 4.76 nM and 6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively. CZC-25146 prevents mutant LRRK2-induced injury of cultured rodent and human neurons with mid-nanomolar potency. CZC-25146 inhibited the activity of recombinant human wild-type LRRK2 with an IC50 ranging from 1 to 5 nM. The G2019S mutant was inhibited with an IC50 ranging from ～2 to ～7 nM in a TF-FRET assay. In addition, they were screened against a kinase panel of 185 kinases and exhibited good selectivity. CZC-25146 (19) inhibited five other kinases, PLK4, GAK, TNK1, CAMKK2, and PIP4K2C, with high potency only, but none of them have been classified as predictors of genotoxicity or hematopoietic toxicity.
| ln Vitro |
CZC-25146 (0.01-5 μM; 7 days) does neither produce cytotoxicity in human cortical neurons, nor preventing neuronal development[1]. CZC-25146 (0.01-5 μM; 2 days) potently attenuates G2019S LRRK2-mediated toxicity in primary rodent neurons in a concentration-dependent manner with an EC50 of ~100 nM[1]. CZC-25146 (0.06-1000 nM) restores LRRK2 G2019S-induced neurite abnormalities in primary human neurons in a dose-dependent manner[1]. CZC -25146 (14.3 and 28.6 μM; 48 h) dramatically lowers The mutant AAT encoded by the Z allele (ATZ) polymer load and restores AAT secretion in iPSC-Hepatocyte, without compromising cell viability[3].
|
|---|---|
| ln Vivo |
After being injected intravenously into mice, CZC-25146 (1 mg/kg for iv; 5 mg/kg for po; single dosage) shows comparatively strong pharmacokinetic features and a wide distribution throughout the animal body[1]. The overexpressing human polymeric ATZ mice's ATZ polymer levels are decreased by CZC-25146 (250 mg/kg; po; 14 days)[3].
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: Human cortical neurons Tested Concentrations: 0.01, 0.1, 1 and 5 μM Incubation Duration: 7 days Experimental Results: Did not cause cytotoxicity in human cortical neurons at concentrations below 5 μM over a seven-day treatment in culture, nor did it block neuronal development . |
| Animal Protocol |
Animal/Disease Models: Male CD-1 mice[1]
Doses: 1 mg/kg for iv; 5 mg/kg for po Route of Administration: iv and po; single dosage Experimental Results: pharmacokinetic/PK Parameters of CZC-25146 in male CD-1 mice[1]. iv (1 mg/kg) po (5 mg/kg) CL (L/h/kg) 2.3 Vss (L /kg) 5.4 t1/2 (h) 1.6 1 tmax (h) 0 0.25 Cmax (ng/mL) 154 1357 AUClast (ng/mL·h) 419 2878 AUCinf (ng/mL·h) 434 2894 F (%) 133 Animal/Disease Models: Genetically modified male mice (6 weeks; over expressing human polymeric ATZ)[3] Doses: 250 mg/kg Route of Administration: po; 14 days Experimental Results: Dramatically and reproducibly decreased the ATZ polymer levels with an overall reduction from 60% in the control group to 37% |
| References |
|
| Molecular Formula |
C22H25N6O4FS
|
|
|---|---|---|
| Molecular Weight |
488.5351
|
|
| Exact Mass |
524.14
|
|
| CAS # |
1191911-26-8
|
|
| Related CAS # |
CZC-25146;1191911-26-8
|
|
| PubChem CID |
72193880
|
|
| Appearance |
Pale purple to purple solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
697.4±65.0 °C at 760 mmHg
|
|
| Flash Point |
375.5±34.3 °C
|
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
|
| Index of Refraction |
1.655
|
|
| LogP |
1.5
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
11
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
35
|
|
| Complexity |
737
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CS(=O)(NC1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCOCC4)C=C3OC)=NC=C2F)=O
|
|
| InChi Key |
SKYQTYQDKAOHLP-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C22H25FN6O4S.ClH/c1-32-20-13-15(29-9-11-33-12-10-29)7-8-19(20)26-22-24-14-16(23)21(27-22)25-17-5-3-4-6-18(17)28-34(2,30)31;/h3-8,13-14,28H,9-12H2,1-2H3,(H2,24,25,26,27);1H
|
|
| Chemical Name |
N-[2-[[5-fluoro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0469 mL | 10.2346 mL | 20.4692 mL | |
| 5 mM | 0.4094 mL | 2.0469 mL | 4.0938 mL | |
| 10 mM | 0.2047 mL | 1.0235 mL | 2.0469 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Chemoproteomics-based discovery of LRRK2 lead compounds.ACS Chem Biol.2011 Oct 21;6(10):1021-8. |
|---|
CZC-25146 and CZC-54252 are potent and selective LRRK2 inhibitors.ACS Chem Biol.2011 Oct 21;6(10):1021-8. |
CZC-25146 and CZC-54252 potently attenuate mutant LRRK2-mediated toxicity in primary human neurons.ACS Chem Biol.2011 Oct 21;6(10):1021-8. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
